Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Merck Foundation Marking "World Diabetes Day" by Providing out of 2080 Scholarships, 830 Scholarships for Diabetes and Hypertension in 52 Countries
Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks ’World Diabetes Day 2024’ together with Africa’s First Ladies, Ministries of Health, Medical Societies and Academia, through their ...
MM&M8h
Merck strikes $3.3B licensing deal for Chinese cancer drug
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
Merck KGaA (MKGAF) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...
newtelegraphng9h
Diabetes Day: Merck Foundation Gives 830 Scholarships To Doctors From 52 Countries
ShareIn commemoration of the 2024 World Diabetes Day, Merck Foundation, the philanthropic arm of Merck KGaA Germany, has ...
BioPharma Dive12h
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Merck KGaA continues focus on strengthening pipeline with external innovation, says CFO on drug trials
Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.
Merck KGaA Earnings Growth Beats Expectations — Update
The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...
Merck KGaA Earnings Growth Beats Expectations
Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...